Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 15,782 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 3,431 · Balance 15,782 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,431 | $3.47 | $11,905.57 |
DisclosureSEC source: 0002079922-26-000006 · form4-10062026_041011.xml · nonDerivative · entry 1 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,782 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 7,453 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0002079922-26-000002 · form4-01062026_080102.xml · derivative · entry 2 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,453 Underlying: Ordinary Shares · 7,453 shares Expires 2036-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 3,726 | $0.00 | $0.00 |
DisclosureSEC source: 0002079922-26-000002 · form4-01062026_080102.xml · nonDerivative · entry 1 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,213 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 102 | $8.55 | $872.10 |
DisclosureSEC source: 0002079922-25-000002 · form4-10062025_041001.xml · nonDerivative · entry 1 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,487 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on October 14, 2024. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001415889-25-021873 · form4-08142025_080808.xml · derivative · entry 2 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2035-08-12 F3 · derivative.exercise_date: This option will vest in three equal installments on each of August 12, 2026, August 12, 2027 and August 12, 2028. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-021873 · form4-08142025_080808.xml · nonDerivative · entry 1 Swanton Robert Charles · CIK 0002079922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,589 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs will vest in three equal installments on each of August 12, 2026, August 12, 2027 and August 12, 2028. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.